Press Room - Sanofi US News
WEB1 day ago · Dr. Fox is a paid advisor to Sanofi for the HERCULES trial. Based on preliminary analysis of the HERCULES study, there was a slight increase in tolebrutinib-treated patients of some adverse events. Liver enzyme elevations (>3xULN) were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group, a …
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB1 day ago · Sanofi's tolebrutinib drug delays progressive MS by 31% in trial. By Ludwig Burger. September 20, 2024 2:07 PM UTC Updated ago ... Reuters, the news and media division of Thomson Reuters, is the ...
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB23 hours ago · Sanofi’s safety and tolerability analysis showed 4.1% of people on tolebrutinib had liver enzyme levels of at least three times the upper limit of normal, compared to 1.6% of the patients taking ...
Sanofi's Tolebrutinib Delays Disability Progression In Patients …
WEB21 hours ago · Friday, Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB18 hours ago · SNY. Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS), The results from the ...
Tolebrutinib Shows Positive Results in Slowing Disability …
WEB1 day ago · Newly announced late-breaking results from the phase 3 HERCULES trial (NCT04411641) showed that tolebrutinib (Sanofi), a Bruton’s tyrosine kinase (BTK) inhibitor, had a significant effect on disability accumulation compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). Presented at the 2024 European Committee for Treatment and Research in ...
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
WEBFeb 23, 2023 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
Novel Agent First to Slow Disability in nrSPMS - Medscape
WEB14 hours ago · September 20, 2024. 0. 0. COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis ...
Press Release: Tolebrutinib demonstrated a 31% delay in time ... - Sanofi
WEB1 day ago · *For participants receiving tolebrutinib. Houman Ashrafian, MD, PhD Head of Research & Development, Sanofi “With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by targeting underlying drivers of the disease. We look forward to discussing these results ...
Press Release: Tolebrutinib demonstrated a 31% delay in time to …
WEB1 day ago · Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show ...